28 Mar 22 | Aurobindo announced that it will acquire certain business assets from Veritaz (the supplier of branded generic formulations and other health care products) for Rs 171 crore on a debt free basis. The acquisition will support Aurobindo’s plans to manufacture biosimilars and other products in India.
28 Mar 22 | Medical Xpress reports on an Institute of Cancer Research, London, study showing that levels of the protein PD-L1 detected in head and neck tumours can be used to personalise medicine. Depending on PD-L1 levels, patients should receive personalised medicine of either chemotherapy with or without cetuximab, pembrolizumab in combination with chemotherapy, or pembrolizumab alone.
29 Mar 22 | Lannett announced that it has commenced dosing in its pivotal trial of biosimilar insulin glargine.
29 Mar 22 | Formycon and Athos KG announced that they have agreed to enter into a long-term strategic partnership regarding biosimilars. As part of this agreement, Formycon will acquire 100% of the rights in FYB202 (biosimilar ustekinumab candidate) and a 50% stake in FYB201 (biosimilar ranibizumab candidate) in exchange for EUR 650 million.
29 Mar 22 | Telix Pharmaceuticals announced that the FDA has designated Telix’s monoclonal antibody TLX66 (90Y-besilesomab) as an orphan drug for use in conditioning treatment of bone marrow prior to hematopoietic stem cell transplant.
Pearce IP offers Australian based, generics and biosimilars focused lawyers, attorneys and regulatory affairs experts, with incomparable global experience, technical competence, and commercial elegance. Call us today on 02 9023 9988 or email info@pearceIP.law.